US and UK versions of the EQ-5D preference weights: Does choice of preference weights make a difference?

Huang, I‐Chan; Willke, Richard J.; Atkinson, Mark J.; Lenderking, William R.; Frangakis, Constantine; Wu, Albert W.

doi:10.1007/s11136-007-9206-4

Cited by 45 publications

(37 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differences between mean utilities estimated by the UK and US tariff are consistent with previous studies that have shown that EQ-5D index scores are slightly higher when using US weights as compared with UK weights [47].…”

Section: Discussionsupporting

confidence: 89%

Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma

Kaufman

Hünger²,

Hennessy

et al. 2017

Future Oncol.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma

Kaufman

Hünger²,

Hennessy

et al. 2017

Future Oncol.

View full text Add to dashboard Cite

“…We used the English scoring system 23 to translate the health states of our participants into utility scores ranging from 0 (worst health) to 1 (perfect health). Although the American and English scoring systems have been found to generate EQ-5D index scores with equivalent psychometric properties in the measurement of quality of life, 24 we verified that our results were consistent when using the American scoring system. 25 …”

Section: Outcome Measuressupporting

confidence: 76%

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

Drolet¹,

Brisson²,

Schmader³

et al. 2010

Canadian Medical Association Journal

251

196

View full text Add to dashboard Cite

H erpes zoster, which is characterized by dermatomal pain and vesicular rash, 1,2 results from reactivation of the varicella-zoster virus. 3,4 The average lifetime risk of herpes zoster in developed countries is estimated to be about 30% [5][6][7] and increases with increasing life expectancy. The most common complication of herpes zoster, and one of the most challenging to treat, is post herpetic neuralgia, a painful condition often defined as pain persisting for more than 90 days after rash onset.8 According to this definition, postherpetic neuralgia is estimated to occur in 8%-27% of people with herpes zoster overall.9-14 The risk of postherpetic neuralgia increases markedly with age. 15The Shingles Prevention Study, a randomized doubleblind placebo-controlled trial, showed that a live-attenuated varicella-zoster virus vaccine was safe and effective in preventing herpes zoster and postherpetic neuralgia among people 60 years of age and older.13 Given these promising results, policy-makers and clinicians are being asked to make recommendations regarding the use and funding of the herpes zoster vaccine. To do this, evidence on the burden of herpes zoster from the patient's perspective is required. The only data available on the impact of herpes zoster on health-related quality of life comes from two short-term studies.16,17 Clinical reports and cross-sectional surveys [18][19][20] have also suggested that post herpetic neuralgia can profoundly impair quality of life. However, no study followed a cohort of patients with newly diagnosed herpes zoster for a sufficient period to assess postherpetic neuralgia and describe the associated impact on quality of life.We undertook a multicentre prospective study to describe the impact of herpes zoster and postherpetic neuralgia on health-related quality of life.

show abstract

“…It comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) which can be rated with either three or five levels of severity (ranging from no problems to extreme problems) depending on the precise measure chosen. 129,130 Scores from the health states are converted through value sets (or preference weights) obtained from general population studies to generate a single utility value. 129,130 This utility ranges from 0.59 to 1 and represents health on a continuum from worst to best (negative values are valued as worse than dead).…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…129,130 Scores from the health states are converted through value sets (or preference weights) obtained from general population studies to generate a single utility value. 129,130 This utility ranges from 0.59 to 1 and represents health on a continuum from worst to best (negative values are valued as worse than dead). The value sets applied can be derived using either a VAS or time trade-off (TTO) technique.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…Neither study protocol mentions the tariff used in calculation of EQ-5D health state values but it may be assumed to be the US tariff. Huang and colleagues 129 note that for assessing treatment benefit in a single population, the use of either the UK or the US EQ-5D weights as a measure of HRQoL will not change inferences.…”

Section: Unprogressed and Progressed Idiopathic Pulmonary Fibrosismentioning

confidence: 99%

See 1 more Smart Citation

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Loveman

Copley

Colquitt

et al. 2015

Health Technology Assessment

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available.ObjectivesTo conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and quality of life.Data sourcesEleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.MethodsTwo reviewers independently screened references for the systematic reviews, extracted and checked data from the included studies and appraised their risk of bias. An advisory group was consulted about the choice of interventions until consensus was reached about eligibility. A narrative review with meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is 3.5% for costs and health benefits.ResultsFourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, threeN-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good, with a low risk of bias. The current evidence suggests that some treatments appear to be clinically effective. The model base-case results show increased survival for five pharmacological treatments, compared with best supportive care, at increased cost. General recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.LimitationsFew direct comparisons of treatments were identified. An indirect comparison through a NMA was performed; however, caution is recommended in the interpretation of these results. In relation to the economic model, there is an assumption that pharmacological treatments have a constant effect on the relative rate of per cent predicted forced vital capacity decline.ConclusionsFew interventions have any statistically significant effect on IPF and a lack of studies on palliative care approaches was identified. Research is required into the effects of symptom control interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis once the results of ongoing studies are reported.Study registrationThis study is registered as PROSPERO CRD42012002116.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

US and UK versions of the EQ-5D preference weights: Does choice of preference weights make a difference?

Cited by 45 publications

References 44 publications

Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma

Nonprogression with Avelumab Treatment Associated with Gains in Quality of Life in Metastatic Merkel Cell Carcinoma

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Contact Info

Product

Resources

About